{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:35:57Z","timestamp":1793871357711,"version":"4.6.1"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"Importance<\/jats:title>Neuroleptic and benzodiazepine medications are often considered for patients with persistent agitated delirium in the last days of life; however, the risk-to-benefit ratio of these medications is ill-defined and benzodiazepine medications have not been compared to placebo.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the effect of scheduled haloperidol, lorazepam, haloperidol plus lorazepam, and placebo on patients with advanced cancer and delirium and experiencing restlessness and\/or agitation in the palliative care setting.<\/jats:p><\/jats:sec>Design, Settings, and Participants<\/jats:title>This multicenter randomized clinical trial was conducted at 3 acute palliative care units in Taiwan and the US with patients with advanced cancer experiencing persistent restlessness and\/or agitation despite nonpharmacologic therapies and standard-dose haloperidol. Among 245 eligible patients, 111 were enrolled, and 75 received blinded treatments. Participants were randomized in a 1:1:1:1 ratio (stratified by site and Richmond Agitation-Sedation Scale [RASS] score). The study period was from July 16, 2019, to June 8, 2023, with a 30-day follow-up after medication administration. Data analysis was performed from October 10, 2023, to April 11, 2025.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Scheduled intravenous haloperidol, lorazepam, haloperidol plus lorazepam, or placebo every 4 hours until discharge, death, or withdrawal from study. Medications in all 4 groups had identical volume and appearance.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Change in RASS scores during the first 24 hours. Secondary outcomes included the use of rescue neuroleptics or benzodiazepines for breakthrough restlessness or agitation during the first 24 hours, delirium severity, perceived patient comfort, and adverse events.<\/jats:p><\/jats:sec>Results<\/jats:title>The primary outcome was assessed in 72 patients (mean [SD] age, 64 [12] years, 42 male [58%]) with a median (IQR) MDAS score of 24 (18-29). The lorazepam group had significantly lower RASS scores than the haloperidol group (mean difference, \u22122.1; 95% CI, \u22123.4 to \u22120.9; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and the combination group had significantly lower RASS scores than the haloperidol group (\u22122.0; 95% CI, \u22123.2 to \u22120.8; P<\/jats:italic>\u2009=\u2009.002); however, there was no difference observed between haloperidol and placebo groups (\u22120.5; 95% CI, \u22121.7 to 0.7; P<\/jats:italic>\u2009=\u2009.42) nor between the combination and lorazepam groups (0.2; 95% CI, \u22121.1 to 1.4; P<\/jats:italic>\u2009=\u2009.79). The combination and lorazepam groups required fewer rescue medications for breakthrough restlessness or agitation compared to the haloperidol and placebo groups (32%, 37%, 56%, 83%, respectively; P<\/jats:italic>\u2009=\u2009.006). Adverse events or survival did not differ between groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The results of this randomized clinical trial indicate that proactive use of scheduled sedatives, particularly lorazepam-based regimens, may reduce persistent restlessness and\/or agitation in patients with advanced cancer and delirium in the palliative care setting.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>Clinicaltrials.gov Identifier: NCT03743649<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.2212","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:30:52Z","timestamp":1753975852000},"page":"1031","source":"Crossref","is-referenced-by-count":18,"title":["Proportional Sedation for Persistent Agitated Delirium in Palliative Care"],"prefix":"10.1001","volume":"11","author":[{"given":"David","family":"Hui","sequence":"first","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"De La Rosa","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Shiun","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, College of Medicine and Hospital, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Yi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, College of Medicine and Hospital, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Del Fabbro","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond"},{"name":"Division of Palliative Medicine, Department of Medicine, Medical College of Georgia, Augusta University, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Thankam","family":"Thomas Kuzhiyil","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Azhar","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-An","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, College of Medicine and Hospital, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Liang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, College of Medicine and Hospital, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Kuei","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, College of Medicine and Hospital, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, College of Medicine and Hospital, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Admane","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony","family":"Dev","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bramati","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Shete","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation, and Integrative Medicine, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"coi250038r1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/082585971102700210","article-title":"Neuroleptic prescription pattern for delirium in patients with advanced cancer.","volume":"27","author":"Hui","year":"2011","journal-title":"J Palliat Care"},{"issue":"1","key":"coi250038r2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jpainsymman.2005.06.007","article-title":"A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease.","volume":"31","author":"Solano","year":"2006","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"coi250038r3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/082585971403000403","article-title":"Palliative care for delirium in patients in the last weeks of life: the final frontier.","volume":"30","author":"Hui","year":"2014","journal-title":"J Palliat Care"},{"issue":"2","key":"coi250038r4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrclinonc.2014.147","article-title":"Delirium in patients with cancer: assessment, impact, mechanisms and management.","volume":"12","author":"Lawlor","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"coi250038r5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jjco\/hym155","article-title":"Prevalence, detection and treatment of delirium in terminal cancer inpatients: a prospective survey.","volume":"38","author":"Fang","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"coi250038r6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1191\/0269216304pm879oa","article-title":"Delirium in advanced cancer patients.","volume":"18","author":"Centeno","year":"2004","journal-title":"Palliat Med"},{"issue":"6","key":"coi250038r7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jpainsymman.2007.01.012","article-title":"Terminal delirium: recommendations from bereaved families\u2019 experiences.","volume":"34","author":"Morita","year":"2007","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"coi250038r8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pon.4140","article-title":"The experiences of caregivers of patients with delirium, and their role in its management in palliative care settings: an integrative literature review.","volume":"26","author":"Finucane","year":"2017","journal-title":"Psychooncology"},{"issue":"2","key":"coi250038r9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jpainsymman.2014.05.009","article-title":"End-of-life delirium: issues regarding recognition, optimal management, and the role of sedation in the dying phase.","volume":"48","author":"Bush","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"12","key":"coi250038r10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1634\/theoncologist.2015-0115","article-title":"The frequency, characteristics, and outcomes among cancer patients with delirium admitted to an acute palliative care unit.","volume":"20","author":"de la Cruz","year":"2015","journal-title":"Oncologist"},{"issue":"23","key":"coi250038r11","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.3390\/cancers13235893","article-title":"Delirium in palliative care.","volume":"13","author":"Bramati","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"coi250038r12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004770.pub3","article-title":"Drug therapy for delirium in terminally ill adults.","volume":"1","author":"Finucane","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"coi250038r13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamainternmed.2016.7491","article-title":"Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial.","volume":"177","author":"Agar","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"7","key":"coi250038r14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(20)30307-7","article-title":"Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.","volume":"21","author":"Hui","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"coi250038r15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jama.2017.11468","article-title":"Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial.","volume":"318","author":"Hui","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"coi250038r16","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3390\/cancers16112045","article-title":"Pharmacologic management of end-of-life delirium: translating evidence into practice.","volume":"16","author":"Hui","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"coi250038r17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/02692163231220225","article-title":"Revised European Association for Palliative Care (EAPC) recommended framework on palliative sedation: an international Delphi study.","volume":"38","author":"Surges","year":"2024","journal-title":"Palliat Med"},{"issue":"4","key":"coi250038r18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jpainsymman.2023.12.016","article-title":"Addressing challenges with sedation in end-of-life care.","volume":"67","author":"Thomas","year":"2024","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"coi250038r19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jpainsymman.2020.06.019","article-title":"Changing practices in the use of continuous sedation at the end of life: a systematic review of the literature.","volume":"60","author":"Heijltjes","year":"2020","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"coi250038r20","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.jpainsymman.2021.06.005","article-title":"Efficacy of proportional sedation and deep sedation defined by sedation protocols: a multicenter, prospective, observational comparative study.","volume":"62","author":"Imai","year":"2021","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"coi250038r21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jpainsymman.2021.07.012","article-title":"Physicians\u2019 opinion and practice with the continuous use of sedatives in the last days of life.","volume":"63","author":"Heijltjes","year":"2022","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"coi250038r22","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.2107138","article-title":"The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients.","volume":"166","author":"Sessler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"coi250038r23","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/cncr.31312","article-title":"The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.","volume":"124","author":"Hui","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"coi250038r24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0885-3924(96)00316-8","article-title":"The Memorial Delirium Assessment Scale.","volume":"13","author":"Breitbart","year":"1997","journal-title":"J Pain Symptom Manage"},{"issue":"11","key":"coi250038r25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00520-007-0247-6","article-title":"Evaluation of the memorial delirium assessment scale (MDAS) for the screening of delirium by means of simulated cases by palliative care health professionals.","volume":"15","author":"Fadul","year":"2007","journal-title":"Support Care Cancer"},{"issue":"22","key":"coi250038r26","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1001\/jama.289.22.2983","article-title":"Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS).","volume":"289","author":"Ely","year":"2003","journal-title":"JAMA"},{"issue":"12","key":"coi250038r27","doi-asserted-by":"publisher","first-page":"7887","DOI":"10.1007\/s00520-021-06384-6","article-title":"Association among rescue neuroleptic use, agitation, and perceived comfort: secondary analysis of a randomized clinical trial on agitated delirium.","volume":"29","author":"Tang","year":"2021","journal-title":"Support Care Cancer"},{"key":"coi250038r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"coi250038r30","first-page":"5","article-title":"Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat).","volume":"55","author":"Lindstr\u00f6m","year":"2001","journal-title":"Nord J Psychiatry"},{"issue":"2","key":"coi250038r31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/082585979100700202","article-title":"The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients.","volume":"7","author":"Bruera","year":"1991","journal-title":"J Palliat Care"},{"issue":"3","key":"coi250038r32","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton Symptom Assessment System 25 years later: past, present, and future developments.","volume":"53","author":"Hui","year":"2017","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"coi250038r33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1176\/appi.psy.43.3.183","article-title":"The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses\/caregivers, and their nurses.","volume":"43","author":"Breitbart","year":"2002","journal-title":"Psychosomatics"},{"issue":"1","key":"coi250038r34","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.jpainsymman.2022.09.015","article-title":"Should neuroleptics be used in patients with delirium seen by palliative care?","volume":"65","author":"Hui","year":"2023","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"coi250038r35","doi-asserted-by":"publisher","first-page":"504","DOI":"10.21037\/apm.2019.03.06","article-title":"Benzodiazepines and\/or neuroleptics for the treatment of delirium in palliative care? a critical appraisal of recent randomized controlled trials.","volume":"8","author":"Gaertner","year":"2019","journal-title":"Ann Palliat Med"},{"issue":"26","key":"coi250038r36","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1808217","article-title":"Haloperidol and ziprasidone for treatment of delirium in critical illness.","volume":"379","author":"Girard","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"coi250038r37","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2211868","article-title":"Haloperidol for the treatment of delirium in ICU patients.","volume":"387","author":"Andersen-Ranberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"coi250038r38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/jamapsychiatry.2018.4365","article-title":"Association of delirium response and safety of pharmacological interventions for the management and prevention of delirium: a network meta-analysis.","volume":"76","author":"Wu","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"coi250038r39","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jpainsymman.2013.10.019","article-title":"Variations in vital signs in the last days of life in patients with advanced cancer.","volume":"48","author":"Bruera","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"coi250038r40","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00520-012-1587-4","article-title":"Clinical changes in terminally ill cancer patients and death within 48 h: when should we refer patients to a separate room?","volume":"21","author":"Hwang","year":"2013","journal-title":"Support Care Cancer"},{"issue":"1","key":"coi250038r41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/BF02245249","article-title":"Extrapyramidal side effects of clozapine and haloperidol.","volume":"118","author":"Kurz","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"coi250038r42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1089\/jpm.2022.0308","article-title":"Chlorpromazine\u2019s potential role in palliating distressing symptoms associated with hyperactive delirium in patients at end of life.","volume":"26","author":"Tiefenthaler","year":"2023","journal-title":"J Palliat Med"},{"issue":"9","key":"coi250038r43","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1089\/jpm.2017.0669","article-title":"factors associated with the effectiveness of intravenous administration of chlorpromazine for delirium in patients with terminal cancer.","volume":"21","author":"Hasuo","year":"2018","journal-title":"J Palliat Med"},{"issue":"3","key":"coi250038r44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4143\/crt.2013.229","article-title":"Frequency and outcome of neuroleptic rotation in the management of delirium in patients with advanced cancer.","volume":"47","author":"Shin","year":"2015","journal-title":"Cancer Res Treat"},{"issue":"3","key":"coi250038r45","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00134-003-2117-0","article-title":"Olanzapine vs haloperidol: treating delirium in a critical care setting.","volume":"30","author":"Skrobik","year":"2004","journal-title":"Intensive Care Med"},{"issue":"1","key":"coi250038r46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13063-022-06238-4","article-title":"An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home.","volume":"23","author":"Lyu","year":"2022","journal-title":"Trials"},{"issue":"4","key":"coi250038r47","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1017\/S1478951514001059","article-title":"Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects.","volume":"13","author":"Boettger","year":"2015","journal-title":"Palliat Support Care"},{"key":"coi250038r48","doi-asserted-by":"publisher","first-page":"iv143","DOI":"10.1093\/annonc\/mdy147","article-title":"Delirium in adult cancer patients: ESMO Clinical Practice Guidelines.","volume":"29","author":"Bush","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"coi250038r49","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2023.0239","article-title":"subcutaneous vs intravenous administration of medications and fluids for patients with cancer in the US and Canada.","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi250038r50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0885-3924(05)80007-7","article-title":"Subcutaneous infusions for control of cancer symptoms.","volume":"5","author":"Storey","year":"1990","journal-title":"J Pain Symptom Manage"},{"key":"coi250038r28","unstructured":"US National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. 2017. Accessed October 18, 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2837082\/jamaoncology_hui_2025_oi_250038_1757953472.52847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:19:06Z","timestamp":1758208746000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2837082"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.2212","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}